Literature DB >> 7476906

Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.

V Gerzanich1, X Peng, F Wang, G Wells, R Anand, S Fletcher, J Lindstrom.   

Abstract

Pharmacological properties of the (+)- and (-)-isomers of synthetic epibatidine, exo-2-(6-chloro-3-pyridyl)-7-azabicyclo-[2.2.1]heptane, were compared with nicotine and acetylcholine on several subtypes of chicken and human nicotinic acetylcholine receptors (AChRs). Both isomers of epibatidine behaved as extremely potent full agonists on chicken (alpha 3 beta 2, alpha 3 beta 4, alpha 4 beta 2, alpha 7, and alpha 8) and human (alpha 3 beta 2, alpha 3 beta 4, and alpha 7) neuronal AChRs expressed in Xenopus oocytes. Currents induced by epibatidine were effectively blocked by the nicotinic antagonists hexamethonium and mecamylamine. Apparent affinity was 100 to 1000-fold higher for epibatidine than for nicotine or acetylcholine. EC50 values ranged from 1 nM (for homomeric chicken alpha 8) to 2 microM (for homomeric chicken alpha 7). Epibatidine showed comparatively lower affinity for muscle-type AChRs from Torpedo and humans (EC50 values, 1.6 and 16 microM respectively). In binding assays, epibatidine was used on AChR subtypes immunoisolated from chicken brain and retina (alpha 4 beta 2, alpha 7, and alpha 8), the human neuronal cell line SH-SY5Y (alpha 3 and alpha 7), Torpedo electric organ (alpha 1 beta 1 gamma delta), or the human rhabdomyosarcoma cell line TE671 (alpha 1 beta 1 gamma delta). Both isomers of epibatidine exhibited extremely high affinity for all neuronal AChRs tested, with KI values ranging from 0.6 pM (human alpha 3 AChRs) to 0.6 microM (chicken alpha 7 AChRs). In contrast, epibatidine had lower affinity for Torpedo muscle-type AChRs (KI approximately 5 microM). Racemic [3H]epibatidine was an effective labeling reagent for human alpha 3 beta 2 AChRs, exhibiting a KD (0.14 nM) similar to the KI values observed for unlabeled (+)-epibatidine (0.23 nM) or (-)-epibatidine (0.16 nM).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7476906

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  56 in total

1.  The regulation of hippocampal nicotinic acetylcholine receptors (nAChRs) after a protracted treatment with selective or nonselective nAChR agonists.

Authors:  J Auta; P Longone; A Guidotti; E Costa
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

2.  Direct recording of nicotinic responses in presynaptic nerve terminals.

Authors:  J S Coggan; J Paysan; W G Conroy; D K Berg
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

3.  Luminal cholinergic signalling in airway lining fluid: a novel mechanism for activating chloride secretion via Ca²⁺-dependent Cl⁻ and K⁺ channels.

Authors:  Monika I Hollenhorst; Katrin S Lips; Miriam Wolff; Jürgen Wess; Stefanie Gerbig; Zoltan Takats; Wolfgang Kummer; Martin Fronius
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  The nicotinic receptor antagonists abolish pathobiologic effects of tobacco-derived nitrosamines on BEP2D cells.

Authors:  Juan Arredondo; Alex I Chernyavsky; Sergei A Grando
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

5.  A Bioinspired Platform for Effective Delivery of Protein Therapeutics to the Central Nervous System.

Authors:  Di Wu; Meng Qin; Duo Xu; Lan Wang; Chaoyong Liu; Jie Ren; George Zhou; Chen Chen; Fengmei Yang; Yanyan Li; Yuan Zhao; Ruyi Huang; Sina Pourtaheri; Chunsheng Kang; Masakazu Kamata; Irvin S Y Chen; Zhanlong He; Jing Wen; Wei Chen; Yunfeng Lu
Journal:  Adv Mater       Date:  2019-02-25       Impact factor: 30.849

6.  Characterization of the adverse effects of nicotine on placental development: in vivo and in vitro studies.

Authors:  A C Holloway; A Salomon; M J Soares; V Garnier; S Raha; F Sergent; C J Nicholson; J J Feige; M Benharouga; N Alfaidy
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-24       Impact factor: 4.310

7.  Two mutations linked to nocturnal frontal lobe epilepsy cause use-dependent potentiation of the nicotinic ACh response.

Authors:  A Figl; N Viseshakul; N Shafaee; J Forsayeth; B N Cohen
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

8.  Alpha3beta4-nicotinic receptors mediate adrenergic nerve- and peptidergic (CGRP) nerve-dependent vasodilation induced by nicotine in rat mesenteric arteries.

Authors:  S Eguchi; S Miyashita; Y Kitamura; H Kawasaki
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

9.  [¹²⁵I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors.

Authors:  Jinhua Wu; David C Perry; James E Bupp; Faming Jiang; Willma E Polgar; Lawrence Toll; Nurulain T Zaveri
Journal:  Neuropharmacology       Date:  2013-10-03       Impact factor: 5.250

10.  Auto/paracrine control of inflammatory cytokines by acetylcholine in macrophage-like U937 cells through nicotinic receptors.

Authors:  Alexander I Chernyavsky; Juan Arredondo; Maryna Skok; Sergei A Grando
Journal:  Int Immunopharmacol       Date:  2009-12-18       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.